NCT03870464Active, not recruiting
LIFE - Lung Cancer, Immunotherapy, Frailty, Effect
The Impact of Age and Comorbidity on Effect of Treatment, Adverse Effects and Quality of Life in Danish Lung Cancer Patients Receiving Immunotherapy
Source: ClinicalTrials.gov · Last updated 7 May 2024
Brief summary (registry, in English)
The LIFE study (Lung cancer, Immunotherapy, Frailty, Effect) is investigating the unselected 'real life' non-small cell lung cancer (NSCLC) population treated with immune checkpoint inhibition.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 150 (actual)
- First submitted
- 1 Mar 2019
- Start date
- 1 Apr 2018
- Primary completion date
- 8 Nov 2022
- Lead sponsor
- University of Southern Denmark
- Diseases
- Lung cancer
- NCT number
- NCT03870464
What you commit to
- Study type: Observational
- Participants enrolled: 150
- From 1 Apr 2018 to the primary completion date, 8 Nov 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- none
Who the study is looking for
- Age \> 18 years
- Stage IV NSCLC or recurrent NSCLC.
- Squamous or non-squamous histology
- Any treatment-line - Independent of prior treatment
- Candidate for checkpoint inhibitor (PD-1/PD-L1 targeting agents) immunotherapy
- No previously known allergy to PD-1/PD-L1 targeting agents.
- Able to give written consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Oncology, Odense University Hospital Coordinator of this site? Confirm its status | Odense | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.